Cargando…

HER-2-Targeted Nanoparticles for Breast Cancer Diagnosis and Treatment

SIMPLE SUMMARY: Despite tremendous efforts in finding new therapeutic strategies and promoting screening programs to increase early diagnosis, breast cancer is still a major cause of death in the female worldwide population. Preclinical and clinical evidence have shown that nanotechnologies can sign...

Descripción completa

Detalles Bibliográficos
Autores principales:	Sitia, Leopoldo, Sevieri, Marta, Signati, Lorena, Bonizzi, Arianna, Chesi, Arianna, Mainini, Francesco, Corsi, Fabio, Mazzucchelli, Serena
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2022
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9139811/ https://www.ncbi.nlm.nih.gov/pubmed/35626028 http://dx.doi.org/10.3390/cancers14102424

Ejemplares similares

Protein-Based Nanoparticles for the Imaging and Treatment of Solid Tumors: The Case of Ferritin Nanocages, a Narrative Review
por: Mainini, Francesco, et al.
Publicado: (2021)

Tumor Accumulation and Off-Target Biodistribution of an Indocyanine-Green Fluorescent Nanotracer: An Ex Vivo Study on an Orthotopic Murine Model of Breast Cancer
por: Sevieri, Marta, et al.
Publicado: (2021)

Indocyanine Green Nanoparticles: Are They Compelling for Cancer Treatment?
por: Sevieri, Marta, et al.
Publicado: (2020)

Development of Tumor-Targeted Indocyanine Green-Loaded Ferritin Nanoparticles for Intraoperative Detection of Cancers
por: Sitia, Leopoldo, et al.
Publicado: (2020)

Novel Bioengineering Strategies to Improve Bioavailability and In Vivo Circulation of H-Ferritin Nanocages by Surface Functionalization
por: Sevieri, Marta, et al.
Publicado: (2023)

Ultrastructural analysis of breast cancer patient-derived organoids
por: Signati, Lorena, et al.
Publicado: (2021)

Everolimus Nanoformulation in Biological Nanoparticles Increases Drug Responsiveness in Resistant and Low-Responsive Breast Cancer Cell Lines
por: Bonizzi, Arianna, et al.
Publicado: (2019)

Combined Method to Remove Endotoxins from Protein Nanocages for Drug Delivery Applications: The Case of Human Ferritin
por: Silva, Filippo, et al.
Publicado: (2021)

In Vitro Immunoreactivity Evaluation of H-Ferritin-Based Nanodrugs
por: Sitia, Leopoldo, et al.
Publicado: (2023)

Selective Targeting of Cancer-Associated Fibroblasts by Engineered H-Ferritin Nanocages Loaded with Navitoclax
por: Sitia, Leopoldo, et al.
Publicado: (2021)

Multivalent exposure of trastuzumab on iron oxide nanoparticles improves antitumor potential and reduces resistance in HER2-positive breast cancer cells
por: Truffi, Marta, et al.
Publicado: (2018)

Development and Validation of a Bioanalytical UHPLC-MS/MS Method Applied to Murine Liver Tissue for the Determination of Indocyanine Green Loaded in H-Ferritin Nanoparticles
por: Sottani, Cristina, et al.
Publicado: (2022)

Nano-Strategies to Target Breast Cancer-Associated Fibroblasts: Rearranging the Tumor Microenvironment to Achieve Antitumor Efficacy
por: Truffi, Marta, et al.
Publicado: (2019)

HDL Dysfunctionality: Clinical Relevance of Quality Rather Than Quantity
por: Bonizzi, Arianna, et al.
Publicado: (2021)

Bisdemethoxycurcumin (BDC)-Loaded H-Ferritin-Nanocages Mediate the Regulation of Inflammation in Alzheimer’s Disease Patients
por: Gagliardi, Stella, et al.
Publicado: (2022)

Co-administration of H-ferritin-doxorubicin and Trastuzumab in neoadjuvant setting improves efficacy and prevents cardiotoxicity in HER2 + murine breast cancer model
por: Andreata, F., et al.
Publicado: (2020)

Anti-MAdCAM-1-Conjugated Nanocarriers Delivering Quantum Dots Enable Specific Imaging of Inflammatory Bowel Disease
por: Truffi, Marta, et al.
Publicado: (2020)

Establishment and Morphological Characterization of Patient-Derived Organoids from Breast Cancer
por: Mazzucchelli, S., et al.
Publicado: (2019)

Lipofilling in Breast Oncological Surgery: A Safe Opportunity or Risk for Cancer Recurrence?
por: Piccotti, Francesca, et al.
Publicado: (2021)

HER Tyrosine Kinase Family and Rhabdomyosarcoma: Role in Onset and Targeted Therapy
por: De Giovanni, Carla, et al.
Publicado: (2021)

Preoperative Systemic Inflammatory Biomarkers Are Independent Predictors of Disease Recurrence in ER+ HER2- Early Breast Cancer
por: Truffi, Marta, et al.
Publicado: (2021)

Nanometronomic treatment of 4T1 breast cancer with nanocaged doxorubicin prevents drug resistance and circumvents cardiotoxicity
por: Mazzucchelli, Serena, et al.
Publicado: (2016)

Natural Nanoparticles: A Safe Bullet for Treatment and Detection of Solid Tumors
por: Mazzucchelli, Serena
Publicado: (2022)

Theranostic application of miR-429 in HER2+ breast cancer
por: Cava, Claudia, et al.
Publicado: (2020)

Preclinical Therapy of Disseminated HER-2(+) Ovarian and Breast Carcinomas with a HER-2-Retargeted Oncolytic Herpesvirus
por: Nanni, Patrizia, et al.
Publicado: (2013)

Advances in Bio-Based Polymers for Colorectal Cancer Treatment: Hydrogels and Nanoplatforms
por: Maspes, Anna, et al.
Publicado: (2021)

Cancer Vaccines Co-Targeting HER2/Neu and IGF1R
por: De Giovanni, Carla, et al.
Publicado: (2019)

Lipid and Polymer-Based Nanoparticle siRNA Delivery Systems for Cancer Therapy
por: Mainini, Francesco, et al.
Publicado: (2020)

Loss of HER2 in breast cancer: biological mechanisms and technical pitfalls
por: Morganti, Stefania, et al.
Publicado: (2022)

The Evolution of Targeted Radionuclide Diagnosis of HER2-Positive Breast Cancer
por: Bragina, O. D., et al.
Publicado: (2022)

Silver Nanoparticles for Water Pollution Monitoring and Treatments: Ecosafety Challenge and Cellulose-Based Hybrids Solution
por: Fiorati, Andrea, et al.
Publicado: (2020)

Tumour homing and therapeutic effect of colloidal nanoparticles depend on the number of attached antibodies
por: Colombo, Miriam, et al.
Publicado: (2016)

HER2-Targeted Multifunctional Silica Nanoparticles Specifically Enhance the Radiosensitivity of HER2-Overexpressing Breast Cancer Cells
por: Yamaguchi, Haruka, et al.
Publicado: (2018)

Reverting estrogen-receptor-negative phenotype in HER-2-overexpressing advanced breast cancer patients exposed to trastuzumab plus chemotherapy
por: Munzone, Elisabetta, et al.
Publicado: (2006)

Target HER four in breast cancer?
por: Brockhoff, Gero
Publicado: (2019)

Internal Quality Assurance Program for ERBB2 (HER2) Testing Improves the Selection of Breast Cancer Patients for Treatment with Trastuzumab
por: Martin, Vittoria, et al.
Publicado: (2012)

Dual targeting of HER3 and MEK may overcome HER3-dependent drug-resistance of colon cancers
por: Bon, Giulia, et al.
Publicado: (2016)

Circulating Fibroblast Activation Protein as Potential Biomarker in Patients With Inflammatory Bowel Disease
por: Corsi, Fabio, et al.
Publicado: (2021)

Correction: Reverting estrogen-receptor-negative phenotype in HER-2-overexpressing advanced breast cancer patients exposed to trastuzumab plus chemotherapy
por: Munzone, Elisabetta, et al.
Publicado: (2006)

Trastuzumab-Targeted Biodegradable Nanoparticles for Enhanced Delivery of Dasatinib in HER2+ Metastasic Breast Cancer
por: Niza, Enrique, et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_7alnrbkjnmv7pvffhoucba7gdi